• Annual Report 2018

    During 2018, we reached an important milestone when the final results from the 1000 patients prospective, multi-center registry study REQUEST was presented. In this study, some of the best cardiac centers in Europe, Canada, and…

    Read more
  • Results for Fourth Quarter and Preliminary Results for Medistim for 2018

    Currency neutral sales of own products increased with 25.5 % for the quarter. For 2018, currency neutral growth in sales of own products was 10.0%. EBIT for the quarter ended at MNOK 27.8 (MNOK 16.4),…

    Read more
  • Results for the Third Quarter 2018

    Sales as of September increased by 4.0 % and ended at MOK 228.0 (MNOK 219.2). Revenue from own products showed a currency neutral decline of 0.4 % for the quarter and a currency neutral growth…

    Read more
  • Results for the Second Quarter 2018

    Sales for the first half of 2018 increased by 4,7 % and ended at MNOK 150,4 (MNOK 143,5). Currency neutral growth of own products was 19,3 % for the second quarter. Operating profit (EBIT) ended…

    Read more
  • Results for the First Quarter 2018

    Currency neutral sales of own products decreased with 2.7 %. Operating profit (EBIT) ended at MNOK 13.6 (MNOK 16.0). Medistims equipment received an updated recommendation by NICE in UK. Data collection in the REQUEST study…

    Read more
  • Annual Report 2017

    We have further strengthened our position within cardiac bypass surgery, in particular in our most important market USA, where we now have achieved a market penetration of 20% measured as the share of bypass procedures…

    Read more
  • Results for the Fourth Quarter and Preliminary Results for 2017

    Currency neutral sales of own products increased by 31.3 % for the quarter. For 2017, currency neutral growth in sales of own products was 15.7%. EBIT for the quarter ended at MNOK 16.4 (MNOK 9.7),…

    Read more
  • Results for the Third Quarter 2017

    Currency neutral growth of own products is 12.5%. Flow probe sales negatively impacted with MNOK 2.2, however, production of flow probe capacity is improving and backorder is reduced from 500 to 250 probes. Another strong…

    Read more
  • Results for the Second Quarter 2017

    Currency neutral growth of own products was 4.7 % and was negatively impacted by delayed flow probe deliveries amounting to MNOK 5.5. Currency neutral growth of own products was 10.7 % for the 1st half.…

    Read more
  • Annual Report 2016

    Sales for the group in 2016 ended at 268.1 MNOK (251.4 MNOK), a 6.6 % growth. Download full report here: Annual Report Medistim 2016

    Read more